Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07427134

Pediatric Insulin Plan Calculator for T1DM Management

This is a multi-centre, prospective, randomized, open-label controlled trial designed to evaluate the effectiveness of a flexible digital insulin dose calculator in children under 12 years of age with Type 1 Diabetes Mellitus (T1DM) managed with multiple daily injections (MDI). Participants will be stratified by continuous glucose monitoring (CGM) use and baseline HbA1c, and randomised to receive either standard care alone or standard care plus the insulin dose calculator tool for 6 months.

The primary outcome is the change in HbA1c from baseline to 6 months. Secondary outcomes include CGM-derived glycaemic metrics (Time in Range, Time Below Range, Time Above Range, and Coefficient of Variation), total daily insulin dose (units/kg/day), healthcare provider contact frequency, and caregiver-reported usability and satisfaction. The study aims to determine whether the use of a structured digital decision-support tool improves glycaemic control and supports safer insulin dosing in paediatric patients with T1DM.

Recruiting

Interested in participating?

Request Info

Key information

Age range

1 year–12 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Mosul, Mosul, Iraq

Loading trial locations.

About this study

Type 1 Diabetes Mellitus (T1DM) in children requires intensive insulin therapy and frequent dose adjustments based on carbohydrate intake, glucose levels, and individualised insulin parameters. Although carbohydrate counting is widely practised in paediatric diabetes management, translating these principles into accurate insulin dosing remains complex. Caregivers must integrate insulin-to-carbohydrate ratios, correction factors, pre-meal glucose values, and -when applicable- continuous glucose monitoring (CGM) trend information. This process is prone to calculation errors and variability, which may contribute to suboptimal glycaemic outcomes.

While advanced technologies such as insulin pumps and hybrid closed-loop systems can automate insulin delivery, many children worldwide continue to use multiple daily injections (MDI). For this population, structured digital decision-support tools may help standardise insulin dose calculations and reduce caregiver burden. However, high-quality prospective evidence evaluating such tools in paediatric MDI users remains limited.

This study is a multi-centre, prospective, randomised, open-label controlled trial evaluating the clinical impact of a flexible digital insulin dose calculator in children under 12 years of age with established T1DM managed with MDI and carbohydrate counting. Participants will be stratified according to CGM use and baseline glycaemic control, then randomised to either standard care alone or standard care plus access to the insulin dose calculator for a 6-month period.

The intervention consists of structured training in the use of the digital calculator, which integrates individualised insulin-to-carbohydrate ratios, correction factors, and glucose inputs to generate dosing recommendations. The study will assess whether integration of this tool into routine care improves overall glycaemic control and glycaemic stability compared with standard practice alone. In addition, the study will explore effects on insulin titration patterns, healthcare utilisation, and caregiver experience.

The trial is designed to reflect real-world paediatric diabetes practice across multiple international sites. Data will be collected during routine clinical encounters over a 6-month follow-up period. The findings are expected to provide evidence regarding the effectiveness, feasibility, and scalability of a non-invasive digital decision-support intervention aimed at improving insulin dosing accuracy and supporting families managing paediatric T1DM.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Children and adolescents < 12 years
  • Diagnosed with Type 1 Diabetes Mellitus (T1DM)
  • Duration of diagnosis > 1 year
  • Using a multiple daily injection (MDI) regimen
  • Practising carbohydrate counting for at least 1 month before enrolment

Exclusion criteria

  • Use of an existing insulin dose calculator (e.g., mobile application or bolus advisor) within the last 3 months
  • Diagnosis of other types of diabetes (e.g., Type 2 diabetes mellitus, monogenic diabetes)
  • Use of insulin regimens other than multiple daily injections (MDI) (e.g., insulin pump therapy)

Treatment and study plan

Flexible Digital Insulin Dose Calculator

Behavioral

The flexible digital insulin dose calculator is a structured decision-support tool designed specifically for children with Type 1 Diabetes Mellitus managed with multiple daily injections and carbohydrate counting. Unlike basic insulin calculation applications that consider limited variables, this tool integrates individualised insulin-to-carbohydrate ratios, correction factors (insulin sensitivity), pre-meal glucose values, and glucose trends (when available) to generate dosing recommendations. The tool is non-automated and does not deliver insulin; it supports caregiver decision-making. It is intended for real-world clinical use and is implemented alongside routine diabetes care with standardised training at baseline. The intervention focuses on improving dosing accuracy and consistency rather than replacing clinician oversight or insulin therapy.

Other names: Insulin Dose Decision-Support Tool

Primary outcomes

  1. Change in HbA1c from Baseline to 6 Months

    Time frame: Baseline to 6 Months

    The primary outcome is the difference in glycated haemoglobin (HbA1c) levels between baseline and 6 months. HbA1c will be measured as part of routine clinical care and analysed to compare changes between the intervention (digital insulin dose calculator plus standard care) and control (standard care alone) groups.

Secondary outcomes

  1. Change in Time in Range (TIR)

    Time frame: Baseline, 3 Months, and 6 Months

    For participants using CGM, change in the percentage of time glucose is within 70-180 mg/dL (4-10 mmol/L) based on CGM reports.

  2. Change in Time Below Range (TBR)

    Time frame: Baseline, 3 Months, and 6 Months

    For participants using CGM, change in the percentage of time glucose is <70 mg/dL (<4 mmol/L) based on CGM reports.

  3. Change in Time Above Range (TAR)

    Time frame: Baseline, 3 Months, and 6 Months

    For participants using CGM, change in the percentage of time glucose is >180 mg/dL (>10 mmol/L) based on CGM reports.

  4. Change in Glucose Coefficient of Variation (CV)

    Time frame: Baseline, 3 Months, and 6 Months

    For participants using CGM, change in glucose coefficient of variation (CV, %) derived from CGM reports as a measure of glycaemic variability.

  5. Change in Total Daily Insulin Dose (units/kg/day)

    Time frame: Baseline, 3 Months, and 6 Months

    Change in total daily insulin dose normalized to body weight (units/kg/day), calculated from clinical records at each assessment time point

  6. Healthcare provider contact frequency during study follow-up

    Time frame: Baseline to 6 Months (assessed at 3 and 6 Months)

    Number of diabetes-related healthcare provider contacts (e.g., clinic, telemedicine, phone consultations) recorded over the study period and/or between visits

  7. Caregiver diabetes distress

    Time frame: Baseline and 6 Months

    Caregiver burden assessed using validated Diabetes Distress Scale instruments, comparing scores over follow-up. PARENT DIABETES DISTRESS SCALE (PARENT-DDS) questionnaire will be used. A mean item score or 0 - 1.9 should be considered "little or no distress," a mean item score between 2.0 - 2.9 should be considered 'moderate distress,' and a mean item score > 3.0 should be considered 'high distress.'

  8. Caregiver usability and satisfaction with the insulin dose calculator

    Time frame: 3 Months and 6 Months

    Structured caregiver questionnaire assessing usability, satisfaction, and perceived value of the digital tool (intervention arm only). System Usability Scale (SUS) questionnaire will be used, which produces a score from 0 to 100 (not a percentage). The higher score indicates better usability. Below 50 means poor usability and >75 = Acceptable for clinical deployment.

Study contacts

Contact information is provided by the study sponsor or research team.

Hussain Alsaffar, FACE, MSc, FRCPCH, CCT, MBChB

CONTACT

[email protected]

0096896399402

Nandu Kumar Thalange, Professor

CONTACT

[email protected]

00971589466920

Sponsors and collaborators

Lead sponsor

Sultan Qaboos University

Other

Collaborators

  • University of Child Health Sciences and Children's Hospital, Lahore
  • University of Mosul

Registry information

Official study title

Prospective, Parallel-Group Randomised Controlled Trial Evaluating a Flexible Insulin Dose Calculator in Paediatric Type 1 Diabetes Management

Acronym: FLEXI-T1D

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Feb 23, 2026
Registry last updated
Jun 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.